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Abstract
Aims/hypothesis Oxidative stress plays a key role in the de-
velopment of type 2 diabetes mellitus. We previously showed
that the circulating antioxidant peroxiredoxin 4 (Prx4) is as-
sociated with cardiometabolic risk factors. We aimed to eval-
uate the association of Prx4 with type 2 diabetes risk in the
general population.
Methods We analysed data on 7,972 individuals from the Pre-
vention of Renal and Vascular End-stage Disease (PREVEND)
study (49%men, aged 28–75 years) with no diabetes at baseline.
Logistic regressionmodels adjusted for age, sex, smoking, waist
circumference, hypertension and family history of diabetes were
used to estimate the ORs for type 2 diabetes.
Results During a median follow up of 7.7 years, 496 individ-
uals (288 men; 58%) developed type 2 diabetes. The median
(Q1–Q3) Prx4 level was 0.84 (0.53–1.40) U/l in individuals
who developed type 2 diabetes and 0.68 (0.43–1.08) U/l in
individuals who did not develop type 2 diabetes. For every
doubling of Prx4 levels, the adjusted OR (95% CI) for type 2
diabetes was 1.16 (1.05–1.29) in the whole population; by
sex, it was 1.31 (1.14–1.50) for men and 1.03 (0.87–1.21) for
women. Further adjustment for other clinical measures did not
materially change the results. The addition of Prx4 to a vali-
dated diabetes risk score significantly improved the prediction
of type 2 diabetes in men (p=0.002 for reclassification
improvement).
Conclusions/interpretation Our findings suggest that elevated
serum Prx4 levels are associated with a higher risk of incident
type 2 diabetes. For men, taking Prx4 into consideration can
improve type 2 diabetes prediction over a validated diabetes
risk score; in contrast, there is no improvement in risk predic-
tion for women.
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Introduction
Type 2 diabetes mellitus is a leading cause of lifelong mor-
bidity and all-cause mortality in many countries worldwide
[1, 2]. The multifactorial and chronic natural history of type 2
diabetes makes it a promising, but challenging, target for
therapeutic intervention in its early stages. Evidence suggests
that oxidative stress plays a key role in the initiation and
progression of type 2 diabetes [3]. Oxidative stress status is
characterised as exposure to reactive oxygen or nitrogen spe-
cies that is not balanced by endogenous antioxidant defences,
resulting in increased oxidative damage [4]. A number of
studies have identified a relationship between oxidation
products or antioxidant levels and the disease state
[4–7]. However, clinical or observational data showing
associations between oxidative stress markers and type 2
diabetes are scarce [5]. Reasons for the current lack of pub-
lished population-based studies include technical difficulties
in biomarker analysis and an absence of reliable assays [5, 8].
The peroxiredoxin (Prx) antioxidant family comprises six
isoforms that have recently been shown to have important
functions in cellular antioxidant defence [9]. Experimental
studies have shown overexpression of intracellular Prx to
occur in animal models of diabetes and obesity [10–12]. Of
the six family members, Prx4 is the only isoform encoded by
the X chromosome (the human PRX4 gene is located on
Xp22.11) and the only one to be secreted into the circulation
[9, 13]. Elevated Prx4 levels appear to protect against diabetes
via both local (e.g. intrahepatic or inside pancreatic beta cells)
and systemic effects on oxidative stress [9, 13]. Prx4 is stable
in the circulation and can be precisely measured using a
validated immunoassay [14]. In a recent study, we found
circulating Prx4 levels to predict cardiovascular disease risk
after accounting for established risk factors [15]. In line with
previous studies, we found a cross-sectional association be-
tween diabetes and elevated Prx4 levels. We also showed that
increased Prx4 levels are associated with some components of
the metabolic syndrome (such as hypertension and
triglycerols) and with well-established inflammatory markers
(such as high sensitivity C-reactive protein [hs-CRP] and
procalcitonin) [14–16].
To the best of our knowledge, the potential association
between Prx4 and type 2 diabetes risk has not been investi-
gated. Therefore, we aimed to investigate whether circulating
Prx4 levels are associated with the development of type 2
diabetes in the general population. Given the sex differences
in oxidative stress defence systems and the location of the
PRX4 gene on the X chromosome, we also performed a
separate analysis in men and women. We used data from a
large population-based cohort study and accounted for poten-
tial variations in Prx4 levels over time.
Methods
Study population and design The Prevention of Renal and
Vascular End-stage Disease (PREVEND) study includes a
Dutch cohort taken from the general population (age range
28–75 years) of Groningen, the Netherlands, between 1997
and 1998. We previously reported details of the study design
and of participant recruitment elsewhere (see electronic
supplementary material [ESM] Methods for further details)
[17, 18]. From the baseline cohort (n=8,592), we first exclud-
ed 331 individuals who had diabetes at baseline. These cases
were defined by self-reporting of a physician diagnosis or by
screening at the first visit (1996–1997). Another 289 partici-
pants with no follow-up data or who could not be linked to a
pharmacy registry were excluded, leaving 7,972 participants
free of baseline diabetes for our cohort analysis. The
PREVEND study was approved by the local medical ethics
committee of the University Medical Center Groningen and
conformed to the principles outlined in the Declaration of
Helsinki. All participants gave written informed consent.
Clinical variables and laboratory markers All participants
attended two outpatient sessions during three rounds of
screening between 1997 and 1998 (baseline examination)
and 1 January 2007 (third examination). Blood samples were
taken after overnight fasting for measuring biomarkers and
stored at −80°C. Prx4 in stored serum samples was measured
using a novel immunoluminometric assay (interassay CV
<20% was 0.51 U/l; intra-assay CV was <8% throughout
range of Prx4 levels) [15]. Details on clinical variables and
laboratory markers were described previously (see ESM
Methods) [15, 19, 20].
Definition of outcome Incident type 2 diabetes was defined if
one or more of the following criteria were met after baseline
recruitment: (1) fasting plasma glucose ≥7.0mmol/l (126mg/dl);
(2) random sample plasma glucose ≥11.1 mmol/l (200 mg/dl);
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(3) self-reporting of a physician diagnosis; and (4) initiation of
glucose-lowering medication use retrieved from a central phar-
macy registry [20].
Statistical analysis We performed a logarithmic transforma-
tion to normalise the distribution of Prx4. Log base 2 (log2)
was used to facilitate the interpretation of results per doubling
of Prx4 levels. First, we prospectively analysed the association
of Prx4 with the risk of new-onset type 2 diabetes using
logistic regression in univariate and multivariable-adjusted
models. In model 1, we adjusted for age and sex (total popu-
lation). In model 2, we also adjusted for smoking, family
history of diabetes, hypertension and waist circumference.
These variables, which are commonly used as predictors of
type 2 diabetes risk, are included in the Data from the Epide-
miological Study on the Insulin Resistance Syndrome
(DESIR) clinical model [21, 22]. Next, we added HDL-
cholesterol, triacylglycerols, glucose, insulin resistance
(defined as HOMA-IR levels above the sex-specific
75th percentile of HOMA-IR distribution) [19, 23, 24],
hs-CRP and 24 h urinary albumin excretion (UAE) in
stepwise adjustments to model 2. We also adjusted for all of
these clinical and biochemical variables in combination with
the variables included in model 2. To investigate potential
sex differences in the association between Prx4 level and
type 2 diabetes, we calculated the interaction term for Prx4 ×
sex in model 2, and stratified analyses by sex. Interaction
terms were considered statistically significant at p<0.10 [25].
Second, to assess the potential prognostic value of Prx4 for
type 2 diabetes risk, we compared the improvement of pre-
diction with the DESIR models, which have been validated in
European populations [22, 26]. The DESIR models were
chosen because they have separate prediction rules for women
and men (see ESM Methods). We calculated the 7.5 year
type 2 diabetes risk based on the DESIR models [26] and on
a model combining the DESIR models and log2Prx4. The
following measures were then calculated to assess the im-
provement in prediction: (1) C-statistic (95% CI), to quantify
the discrimination performance of the models (their ability to
distinguish between individuals with and without new-onset
type 2 diabetes); and (2) integrated discrimination improve-
ment (IDI) and continuous net reclassification improvement
(NRI), to examine whether individuals with and without this
outcome were correctly reclassified [15, 27, 28].
In secondary analyses, we used data from a second Prx4
measurement to account for changes in Prx4 levels over time.
We then fitted fractional polynomials to examine whether the
relationship between Prx4 levels and new-onset type 2 diabetes
is nonlinear (see ESM Methods). A likelihood ratio test was
used to test for nonlinearity (p<0.05).
All statistical analyses were carried out using IBM SPSS
(version 19.0; Chicago, IL, USA) and R (version 2.15.2;
Vienna, Austria; http://75cran.r-project.org/).
Results
Associations of Prx4 with baseline variables and new-onset
type 2 diabetes At baseline, unadjusted median Prx4 levels
with interquartile range (Q1–Q3) were 0.71 (0.45–1.16) U/l in
men and 0.66 (0.42–1.08) U/l in women ( p<0.001). Detailed
characteristics of the total population and the corresponding
tertiles of serum Prx4 are summarised in Table 1. Across Prx4
tertiles, individuals with higher Prx4 levels were older, more
obese, less frequent alcohol drinkers and more likely to have
hypertension and higher cholesterol, triglycerols, glucose,
hs-CRP, procalcitonin and 24 h UAE. During a median
(Q1–Q3) follow up for 7.7 (7.4–8.0) years, 496 individuals
(6.2%) developed type 2 diabetes. A comparison of Prx4
levels in individuals who developed new-onset type 2 diabetes
vs individuals who remained free of disease is shown in ESM
Table 1. Prx4 concentrations were significantly higher in
individuals who developed type 2 diabetes than in individuals
who did not (0.84 [0.53–1.40] and 0.68 [0.43–1.08] U/l,
respectively; p<0.001).
Primary analysis of risk ORs (95% CI) of univariate and
multivariable-adjusted models for the risk of new-onset
type 2 diabetes for the total population and separately for
men and women are shown in Table 2. In the whole popula-
tion, the age- and sex-adjusted OR was 1.55 (1.21–1.99) for
type 2 diabetes when comparing the top tertile to the bottom
tertile of Prx4 ( p for trend <0.001). In clinical model 2,
adjusted for diabetes risk factors, the association of Prx4 with
type 2 diabetes was attenuated, with an OR of 1.24 (0.96–
1.60). The corresponding OR per unit increase in log2Prx4
(i.e. per doubling of Prx4 levels) was 1.16 (1.05–1.29). The
direction and strength of the relationship between log2Prx4
and type 2 diabetes was similar when we refitted the clinical
model and either included BMI instead of waist circumference
(OR 1.16 [1.04–1.29]) or added both waist circumference and
BMI to the same model (OR 1.16 [1.04–1.28]). Separate
adjustments for HDL-cholesterol (OR 1.14 [1.02–1.27]),
triglycerols (OR 1.12 [1.00–1.24]), glucose (OR 1.16 [1.03–
1.29]), insulin resistance (OR 1.11 [1.00–1.24]), hs-CRP
(OR 1.12 [1.00–1.25]) and UAE (OR 1.15 [1.04–1.28])
combined with the DESIR clinical model did not materially
change the association between Prx4 and type 2 diabetes.
When we adjusted for all of these variables in combination
with the DESIR clinical model, the OR was 1.06 (0.93–1.18).
Given the sex-related differences in Prx4 concentration and
diabetes risk factors, we next stratified the analysis by sex. In
men, age-adjusted andmultivariable-adjusted (for the variables
in model 2) ORs for type 2 diabetes were 1.37 (1.20–1.57) and
1.31 (1.14–1.50), respectively, per doubling of Prx4 levels.
When we further adjusted for HDL-cholesterol, triglycerols,
hs-CRP, UAE, insulin resistance and glucose in combination
with the DESIR clinical model, the OR was 1.22 (1.05–1.40).
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In women, the age-adjusted OR for type 2 diabetes was 1.19
(1.01–1.39) per doubling of Prx4 levels. After adjusting for the
variables in model 2, the association was attenuated to non-
significance (OR 1.03 [0.87–1.21]; p=0.70). For the interac-
tion term between Prx4 and sex, there was a trend toward
significance ( p=0.13).
In the whole population, the DESIR clinical and clinical–
biological models had C-statistics (95% CI) of 0.754 (0.734–
0.773) and 0.819 (0.799–0.840), respectively, for new-onset
type 2 diabetes risk. The addition of Prx4 to the clinical model
modestly improved the C-statistic to 0.758 (0.734–0.773;
p=0.02), and led to an IDI of 0.0012 ( p=0.09) and a contin-
uous NRI of 0.14 (p=0.002). The addition of Prx4 to the
clinical–biological model modestly improved the C-statistic to
0.823 (0.802–0.843; p=0.03), and led to an IDI of 0.0013
( p=0.2) and a continuous NRI of 0.15 ( p=0.002). Inmen, the
addition of Prx4 to the DESIR clinical model significantly
improved the C-statistic from 0.701 to 0.710 ( p=0.04), and
improved both the IDI (0.003; p<0.01) and the continuous
NRI (0.21; p<0.001). The DESIR clinical model with the
addition of glucose had a C-statistic of 0.831 (0.807–0.856).
The addition of Prx4 to the DESIR clinical model with glu-
cose minimally improved the C-statistic (change of +0.003;
p=0.33), but led to an IDI of 0.003 ( p=0.04) and a continuous
NRI of 0.15 ( p=0.01) in men. The addition of Prx4 to the
DESIR clinical–biological model, as a second reference
(showing a C-statistic of 0.831), minimally improved the
C-statistic (change of +0.002; p=0.37), but led to an IDI of
Table 1 Baseline clinical and laboratory characteristics of participants
Total Sex-specific Prx4 tertiles
1st 2nd 3rd p value
No. of participants 7, 972 (100) 2,666 (33.4) 2,604 (32.7) 2,702 (33.9) –
Male 3,909 (49.0) 1,311 (49.2) 1,281 (49.2) 1,352 (50.0) 0.9
Age (years) 48.9±12.5 47.1±11.9 48.6±12.2 51.3±13.1 <0.001
Family history of diabetes 1,566 (19.6) 497 (18.6) 512 (19.7) 557 (20.6) 0.19
Smoking <0.001
Never 2,340 (29.4) 747 (28) 777 (29.8) 816 (30.2)
Current 2,738 (34.3) 1,031 (38.7) 896 (34.4) 811 (30.0)
Former 2,894 (36.3) 888 (33.3) 931 (35.8) 1,075 (39.8)
Alcohol use <0.001
≥4 drinks per day 409 (5.1) 115 (4.3) 157 (6.0) 137 (5.1)
1–3 drinks per day 1,566 (19.6) 587 (22.1) 486 (18.7) 493 (18.2)
2–7 drinks per week 2,708 (34.0) 968 (36.3) 912 (35.0) 828 (30.6)
1–4 drinks per month 1,280 (16.1) 409 (15.3) 432 (16.6) 439 (16.2)
Almost never 2,009 (25.2) 587 (22.1) 617 (23.7) 805 (30.0)
Systolic BP (mmHg) 124.0±19.3 121.2±17.6 123.5±18.9 127.1±20.9 <0.001
Diastolic BP (mmHg) 71.7±9.7 70.4±9.1 71.7±9.8 72.8±10.1 <0.001
Hypertension 2,238 (28.1) 576 (21.6) 706 (27.1) 956 (35.4) <0.001
BMI (kg/m2) 26.0±4.2 25.4±3.8 26.0±4.1 26.7±4.5 <0.001
Waist circumference (cm) 88.1±12.9 86.4±12.1 87.8±12.6 90.2±13.6 <0.001
Glucose (mmol/l) 4.7±0.6 4.7±0.6 4.7±0.6 4.8±0.7 <0.001
Insulin (pmol/l) 47.4 (33–70.8) 43.8 (31.2–69.4) 46.8 (32.4–69.6) 53.4 (36–82.2) <0.001
HOMA-IR 1.63 (1.10–2.55) 1.48 (1.03–2.20) 1.61 (1.07–2.47) 1.84 (1.22–3.06) <0.001
Total cholesterol (mmol/l) 5.64±1.12 5.61±1.08 5.62±1.14 5.68±1.14 0.04
HDL cholesterol (mmol/) 1.33±0.40 1.37±0.40 1.33±0.39 1.29±0.4 <0.001
Triacylglycerol (mmol/l) 1.15 (0.84–1.66) 1.12 (0.81–1.56) 1.11 (0.82–2.38) 1.22 (0.88–1.8) <0.001
hs-CRP (mg/l) 1.26 (0.55–2.88) 0.94 (0.42–2.09) 1.21 (0.56–2.73) 1.78 (0.78–3.70) <0.001
Procalcitonin (ng/ml) 0.016 (0.013–0.020) 0.015(0.013–0.019) 0.016 (0.013–0.019) 0.016 (0.013–0.021) <0.001
UAE (mg/24 h) 9.3 (6.3–16.8) 8.7 (6.2–14.2) 9.1 (6.2–15.6) 10.3 (6.4–22.0) <0.001
Data are mean (±SD) andmedian (quartiles 1 and 3) for continuous variables and n (%) for categorical variables in the total population and corresponding
to sex-specific Prx4 tertiles
p values from univariate analyses (for comparison across Prx4 tertiles) were determined using ANOVA orKruskal–Wallis for continuous variables or χ2
tests for categorical variables
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0.0031 ( p=0.04) and a continuous NRI of 0.15 ( p=0.01). In
women, the addition of Prx4 to the DESIR clinical model did
not improve the prediction in terms of discrimination (the
C-statistic changed from 0.823 to 0.824; p=0.31) and reclas-
sification (IDI of 0.0001, p=0.82; continuous NRI of 0.034,
p=0.63).
Secondary analysis of risk Fractional polynomials showed
that the relationship between Prx4 and new-onset type 2
diabetes deviated from linearity ( p for nonlinearity
<0.0001). The best-fit model included the power −0.5
for Prx4 ( p for nonlinear function <0.0001). The model
was adjusted for the DESIR clinical model. Fig. 1 de-
picts the nonlinear relationship between Prx4 and type 2
diabetes. The solid line indicates the ORs (95% CIs)
[26] plotted against the functional form of Prx4. To
estimate the risk of type 2 diabetes at different values
of Prx4, we selected the median Prx4 value as a refer-
ence. Accordingly, the risk of type 2 diabetes increases
steeply within the lower range of Prx4 until a plateau is
reached at the highest values of Prx4. Finally, we
accounted for the variation in Prx4 concentrations over
time in the PREVEND study. Prx4 levels were 0.55
(0.37–0.84) U/l in men and 0.48 (0.37–0.74) U/l in
women at the third examination. The β-coefficient for
regression of the second measurement of Prx4 on the
baseline values of Prx4 was 0.527 for men and 0.491
for women. After adjusting for regression dilution bias,
the OR per single unit increase in log2Prx4 was 1.67
(1.28–2.17) and 1.06 (0.76–1.48) for men and for women,
respectively, in model 2.
Table 2 Association of Prx4 with new-onset type 2 diabetes
Analysis by group Prx4 tertile, U/l OR (95% CI) per log2
unit increase
p value
1st 2nd 3rd
Total (n=7,952)
No. of cases (%) 115 (4.4) 156 (6.0) 225 (8.2) – –
Crude analysis 1.00 1.39 (1.05–1.81) 1.87 (1.45–2.42) 1.37 (1.24–1.52) <0.001
Model 1 1.00 1.29 (1.00–1.59) 1.55 (1.21–1.99) 1.27 (1.15–1.41) <0.001
Model 2 1.00 1.20 (0.92–1.56) 1.24 (0.96–1.60) 1.16 (1.05–1.29) 0.005
Men (n=3,909)
No. of cases (%) 63 (4.8) 85 (6.6) 140 (10.6) – –
Crude analysis 1.00 1.30 (0.90–1.88) 2.32 (1.67–3.27) 1.46 (1.28–1.67) <0.001
Model 1 1.00 1.21 (0.84–1.74) 1.94 (1.40–2.73) 1.37 (1.20–1.57) <0.001
Model 2 1.00 1.14 (0.79–1.64) 1.69 (1.21–2.38) 1.31 (1.14–1.50) <0.001
Women (n=4,063)
No. of cases (%) 55 (4.0) 66 (5.0) 87 (6.3) – –
Crude analysis 1.00 1.03 (0.69–1.53) 1.40 (0.97–2.04) 1.27 (1.07–1.48) 0.004
Model 1 1.00 1.06 (0.72–1.56) 1.28 (0.89–1.85) 1.19 (1.01–1.39) 0.03
Model 2 1.00 1.00 (0.67–1.47) 0.98 (0.67–1.40) 1.03 (0.87–1.21) 0.70
Model 1 is adjusted for age and sex (total population); model 2 is adjusted for the covariates in model 1 and smoking, waist circumference, hypertension
and family history of diabetes
Fig. 1 Nonlinear relationship between Prx4 and new-onset type 2 dia-
betes mellitus. Data are shown for 7,952 participants without diabetes at
baseline. A fractional polynomials model was fitted to examine the
linearity and determine the functional form of Prx4. The optimal trans-
formation of Prx4 was one in which the term Prx4−0.5 was incorporated;
OR for diabetes=exp(β×(x-median)−0.5), where β is the regression coef-
ficient for transformed Prx4 (x). The plotted ORs (solid line) and 95% CI
(shaded area) were calculated for different values of Prx4 compared with
the median Prx4 value, which was used as the reference. Prx,
peroxiredoxin; T2DM, type 2 diabetes mellitus
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Discussion
In this large prospective cohort with no diabetes at baseline, we
demonstrated that circulating Prx4 concentrations are positive-
ly associated with an increased risk of new-onset type 2
diabetes even after adjusting for established diabetes risk
factors. The addition of Prx4 to a validated diabetes risk
score significantly improved risk prediction for new-onset type
2 diabetes in terms of discrimination and reclassification. The
positive relationship between Prx4 and type 2 diabetes was
nonlinear (i.e. curved) and statistically significant for men.
The strengths of our epidemiological study are its large sample
size, prospective design and verification of new-onset type 2
diabetes cases. We used a reliable assay to measure circulating
Prx4 in samples obtained at both baseline and the third examina-
tion. The repeated Prx4 measurement enabled us to account for
potential variations over time or for measurement error using the
regression dilution ratio. Regression dilution bias was described
as attenuation in the estimated effect of exposure to a risk factor
(e.g. Prx4) to disease risk (e.g. type 2 diabetes) when a single
measurement was used [29]. Nevertheless, some limitations of
our study should be stated. The PREVEND cohort predominant-
ly comprises white adults, and it is therefore unclear whether our
findings can be generalised to nonwhite populations. By design,
our cohort was enriched for individuals with urine albumin
concentrations above 10 mg/l at baseline. However, a weighted
method performed to compensate for this did not affect the
results. Nevertheless, we also investigated the adjusted OR for
24 h UAE as a potential confounding factor. Similar to most
observational studies, our cohort was not originally set up to
investigate diabetes. Since individuals with type 2 diabetes can
remain undiagnosed for several months to years, we might there-
fore have missed false-negative cases in the remainder of the
cohort [22]. However, this would weaken the association rather
than generating a false-positive association. Nonetheless, the
incidence of type 2 diabetes in the PREVEND cohort is similar
to current estimates of diabetes in European adults [2]. The study
is an observational investigation; therefore, causal relationships
between Prx4 as an antioxidant biomarker and type 2 diabetes
cannot be inferred. In addition, although we accounted for con-
founding by established diabetes risk factors, the potential for
unobserved confounding remains. Finally, we used logistic re-
gression in our cohort study because disease-associated changes
have been detected at regular screening visits or shortly thereafter
in the PREVEND study. Thus, estimated survival and hazards
cannot be accurately calculated using this type of follow up [22].
However, we and others have shown that survival models do not
necessarily perform better than logistic ones [22, 30].
There is accumulating evidence that the thiol-dependent
antioxidant family member, Prx4, plays a key role in oxidant
scavenging and in signalling cascades that protect against
oxidative damage [9, 11, 31]. In an experimental study of an
animal model of type 1 diabetes, transgenic mice
overexpressing human Prx4 had significantly higher Prx4
expression in pancreatic islets and reduced hyperglycaemia
compared with wild-type mice [11]. In other words, Prx4
supplementation in vivo has a protective effect against diabe-
tes and can lead to improved insulin resistance. Consistent
with this, increased Prx4 gene expression has been observed
after high-fat diet-induced beta cell dysfunction in mice [32].
Increased reactive oxygen species production is a key change
in the development of insulin resistance and in early stage beta
cell dysfunction in both human patients and animal models of
type 2 diabetes [32, 33]. Changes in Prx4 expression regulate
the cellular redox state, and suggest that oxidative metabolism
is enhanced in the islets of animals receiving high-fat or high-
carbohydrate diets [32]. Prx4 may also have a pivotal role in
the suppression of apoptosis and in progenitor cell prolifera-
tion in vivo to protect against oxidative stress-induced beta
cell dysfunction [11].
Moreover, Prx4 is the only Prx familymember known to be
secreted [9, 11, 13, 34]. Cross-sectional in vivo studies in
humans also reported elevated Prx4 in type 2 diabetes patients
[9, 15, 31]. El Eter et al reported significantly higher Prx4
levels in type 2 diabetes patients with peripheral atheroscle-
rotic disease than in healthy controls [31]. Nabeshima et al
also found higher serum Prx4 levels in male patients with
type 2 diabetes than in a group of healthy males [9]. A recent
analysis of clinical data showed increased serum Prx4 levels
in septic patients compared with healthy individuals [16, 35].
In line with the latter study, we previously reported a positive
association between Prx4 levels and inflammatory markers
(such as hs-CRP), measures of adiposity (such as BMI), BP
and glucose [15]. These factors underlie the central biological
pathways of metabolic syndrome and type 2 diabetes [15, 36,
37]. Prx4 may protect against the metabolic abnormalities
leading to type 2 diabetes so that upregulated intracellular
Prx4 synthesis and augmented extracellular Prx4 levels sup-
press oxidative stress and ameliorate local (e.g. hepatic or islet
cells) and systemic inflammatory signalling and insulin sen-
sitivity [9, 38]. Prx4 promotes antioxidant activity via several
pathways, such as nuclear factor-κB (NF-κB) [39], p53 [40],
thromboxane A2 receptor [41] and NF-E2-related factor 2
(Nrf2) [15, 42]. A recent clinical trial showed that treatment
with the Nrf2 antagonist, a specific antioxidant that affects the
Prx4 pathway, is an effective intervention against the decline
in renal function in patients with chronic kidney disease and
type 1 diabetes [15, 43].
In our study, we extended these in vitro and in vivo exper-
imental studies by investigating the relationship between Prx4
and type 2 diabetes. We prospectively examined whether Prx4
has an additive effect on type 2 diabetes prediction. First, we
estimated type 2 diabetes risk in our population using a
validated diabetes risk score. These estimates were then used
to evaluate the predictive value of Prx4 when added to the
DESIR models. In the total population, the addition of Prx4 to
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the DESIR clinical model statistically improved disease pre-
diction in terms of discrimination and reclassification. Given
the sex differences in Prx4 levels and diabetes risk factors, we
next stratified the analysis by sex. We observed that Prx4
predicted the risk of new-onset type 2 diabetes independently
of established diabetes risk factors only in men. In women, the
addition of Prx4 did not improve risk prediction for type 2
diabetes. The reason that the association between Prx4 and
type 2 diabetes is stronger in men than in women is unknown.
The PRX4 gene is located on the X chromosome; therefore,
further studies are necessary to investigate whether potential
differences in gene expression or in sex hormones con-
tributes to differences between men and women in the
Prx4 response to oxidative stress. Finally, our findings re-
quire validation to confirm the utility of Prx4 in type 2
diabetes risk prediction.
In conclusion, our results suggest that elevated circulating
Prx4 is associated with an increased risk of type 2 diabetes,
even after adjusting for diabetes risk factors, in a population-
based cohort study. Prx4 was more strongly associated with
type 2 diabetes risk in men than in women. In men, Prx4
analysis can improve the prediction of type 2 diabetes above
that of a validated diabetes risk score; in contrast, Prx4 showed
no added predictive value in women. Further studies are
warranted to elucidate the underlying mechanisms of action.
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